TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03387098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovaza
Description: Omega-3-acid ethyl esters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study: NCT04119050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as intravenous infusion
Study: NCT03523442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: The participants will receive apalutamide 240 mg once daily orally.
Study: NCT02220465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA+ Smoking Cessation (LMPA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Smoking Counseling (SCC)
Study: NCT00171496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion
Study: NCT03473366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mask
Description: Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
Study: NCT01443338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptergium Wilfordii
Description: Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
Study: NCT00171496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study: NCT00294723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg for s.c. (under the skin) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 8 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 8 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg for s.c. (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, 8mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo, 8mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, 200 mcl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, 300 mcl
Study: NCT01482156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 + BEZ235
Description: RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
Study: NCT02375126

Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.

Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.

Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
Study: NCT04161144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
Study: NCT01570972

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Cognitive Behavioral Therapy
Description: weekly

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multifamily Group Psychoeducation
Description: twice monthly
Study: NCT05713396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril
Description: Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril + Losartan
Description: Per os
Study: NCT01883817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA Omega-3
Description: Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
Study: NCT03065959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reldesemtiv
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reldesemtiv
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT04494061

Intervention type: PROCEDURE
Intervention: blood collection
Description: Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.

Intervention type: PROCEDURE
Intervention: blood collection
Description: Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
Study: NCT04664959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB16 (Proposed Denosumab Biosimilar)
Description: Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB16 (Proposed Denosumab Biosimilar)
Description: Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.
Study: NCT01945853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI
Study: NCT01003483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat
Description: Tablet,120mg,three times a day,three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orlistat
Description: Tablet,120mg,three times a day,three months
Study: NCT04664959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia® (Denosumab)
Description: Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
Study: NCT01594190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity 15 minutes/day
Description: weight-bearing treadmill, pulsereserve increase of 50 %

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity, 2 x 30 minutes/day
Description: weight-bearing treadmill, pulsereserve increase of 50 %
Study: NCT00003762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT03642639

Intervention type: DEVICE
Group type: OTHER
Intervention: MICRUSFRAME and GALAXY coils
Description: MICRUSFRAME and GALAXY Coils
Study: NCT04101487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: Monthly cash transfers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash Transfers and Nutrition Education
Description: Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
Study: NCT00003762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02433821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Study: NCT02982174

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: Image acquisition of the posterior surface of the eye

Intervention type: DEVICE
Intervention: DRI OCT Triton
Description: Image acquisition of the posterior surface of the eye
Study: NCT03719248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
Study: NCT02336360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
Study: NCT02126423

Intervention type: OTHER
Intervention: Conjunctival and nasopharyngeal swabs
Description: For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.

Intervention type: OTHER
Intervention: Conjunctival and nasopharyngeal swabs
Description: For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
Study: NCT00746707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate
Description: adhesive of perineal tears

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3. traditional suturing with vicryl rapid 2X0
Description: suturing of perineal tears grade one with vicryl rapid 2X0
Study: NCT01542437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug.
Study: NCT03545594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered in home rehabilitation
Description: Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual follow-up in the municipality
Study: NCT02048098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: 400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal misoprostol
Description: 400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
Study: NCT04123418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WVT078
Description: WVT078 will be administered IV (intravenously) in a dose escalation schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WVT078
Description: WVT078 will be administered IV (intravenously) in a dose escalation schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WHG626
Description: WHG626 will be administered orally in a dose escalation schedule
Study: NCT04530110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
Study: NCT03512327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autoimmune protocol (AIP) diet
Description: Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
Study: NCT04161144

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
Study: NCT02622204

Intervention type: PROCEDURE
Intervention: Corrective osteotomy
Description: corrective osteotomy for varus alignment
Study: NCT01099384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written self-help materials
Description: Written materials to help adolescents stop tobacco use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group behavioral counseling
Description: group behavioral counseling (2 day weekend program)
Study: NCT03534986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: International Biophysics AffloVest
Description: High-frequency chest wall oscillation vest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: International Biophysics AffloVest
Description: High-frequency chest wall oscillation vest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: International Biophysics AffloVest
Description: High-frequency chest wall oscillation vest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hill-Rom The Vest
Description: High-frequency chest wall oscillation vest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respirtech inCourage
Description: High-frequency chest wall oscillation vest

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromed SmartVest
Description: High-frequency chest wall oscillation vest
Study: NCT02898649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25\~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
Study: NCT02320279

Intervention type: DEVICE
Intervention: Fetal Heart Rate Monitor
Description: Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
Study: NCT00513851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-930
Description: Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
Study: NCT01999998

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT02441127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser group
Description: the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel control group
Description: In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
Study: NCT00513851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-930
Description: Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
Study: NCT03996603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogens Cream
Description: 0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
Study: NCT04175496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Cake
Description: Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snacks with Cheese
Description: Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spicy Crackers
Description: Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution First Repeat
Description: The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution Second Repeat
Description: The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.